Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Lumify
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Results of new investigational in vitro data shows that two benzalkonium chloride preserved eye drops, LUMIFY® redness reliever eye drops and BESIVANCE® 0.6%, indicated complete inactivation of Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2 or COVID-19).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OB-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OB-002
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: National Research Council Industrial Research Assistance Program
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 30, 2020
Details:
Funding from the National Research Council Industrial Research Assistance Program will support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS).
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
